Kailera Therapeutics, Inc. — Form 10-Q
Filed August 12, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Kailera Therapeutics amended employment agreements for CEO Ronald Renaud ($675k base, 60% bonus target, 24-month severance), COO Paul Burgess ($515k base, 40% bonus target, 12-month severance), and Chief Commercial Officer Jamie Coleman ($468k base, 40% bonus target, 12-month severance). All agreements effective upon S-1 registration statement effectiveness (IPO), replace prior agreements, and provide enhanced change-in-control severance (24 months for CEO, 12 months for others) with full equity acceleration. Total annual base compensation for three executives: ~$1.658M.
Why this rating
Routine pre-IPO executive contract standardization. Three executives' combined ~$1.66M annual base is ~0.27% of $624.8M asset base—immaterial. No strategic changes, no material financial commitment relative to company scale.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.